Oscillometry improves earlier than spirometry after benralizumab initiation in severe asthma

Shirai, Toshihiro; Akamatsu, Taisuke; Hirai, Keita; Watanabe, Hirofumi; Tamura, Kanami; Kishimoto, Yutaro; Saigusa, M

doi:10.1111/all.14339

Cited by 15 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…111 A study proposed the addition of oscillometry together with spirometry as it proved useful to assess earlier changes in responders to treatment with benralizumab. 112 Dunn et al 113 The role of eosinophils in personalized asthma treatment remains controversial. In a real-life study, Bagnasco et al showed no correlation between peripheral blood eosinophils count with the clinical, functional, and biological outcome changes in asthma patients.…”

Section: A S Thma D Iag Nos Is Precis I On Med I Cine and B I Omentioning

confidence: 99%

See 1 more Smart Citation

Advances and recent developments in asthma in 2020

Cevhertas

Öğülür

Maurer

et al. 2020

Allergy

128

View full text Add to dashboard Cite

In this review, we discuss recent publications on asthma and review the studies that have reported on the different aspects of the prevalence, risk factors and prevention, mechanisms, diagnosis, and treatment of asthma. Many risk and protective factors and molecular mechanisms are involved in the development of asthma. Emerging concepts and challenges in implementing the exposome paradigm and its application in allergic diseases and asthma are reviewed, including genetic and epigenetic factors, microbial dysbiosis, and environmental exposure, particularly to indoor and outdoor substances. The most relevant experimental studies further advancing the understanding of molecular and immune mechanisms with potential new targets for the development of therapeutics are discussed. A reliable diagnosis of asthma, disease endotyping, and monitoring its severity are of great importance in the management of asthma. Correct evaluation and management of asthma comorbidity/ multimorbidity, including interaction with asthma phenotypes and its value for the precision medicine approach and validation of predictive biomarkers, are further detailed. Novel approaches and strategies in asthma treatment linked to mechanisms and endotypes of asthma, particularly biologicals, are critically appraised. Finally, due to the recent pandemics and its impact on patient management, we discuss the challenges, relationships, and molecular mechanisms between asthma, allergies, SARS-CoV-2, and COVID-19.

show abstract

Section: A S Thma D Iag Nos Is Precis I On Med I Cine and B I Omentioning

confidence: 99%

“…The clinical impact of SAD in asthma is further explored in the longitudinal study 111 . A study proposed the addition of oscillometry together with spirometry as it proved useful to assess earlier changes in responders to treatment with benralizumab 112 …”

Section: Asthma Diagnosis Precision Medicine and Biomarkersmentioning

confidence: 99%

Advances and recent developments in asthma in 2020

Cevhertas

Öğülür

Maurer

et al. 2020

Allergy

128

View full text Add to dashboard Cite

show abstract

“… 2 , 3 RWE studies report greater improvements in lung function, measured with spirometry and other techniques like oscillometry. 40 In our study, improvements exceed 320 mL, with improvement considered clinically relevant, as occurs in most RWE studies, where improvements have been observed even above 680 mL. 35 Exacerbations and lung function were evaluated in studies in SEA population with or without CRSwNP, obtaining better results in the subpopulation with CRSwNP.…”

Section: Discussionmentioning

confidence: 66%

Reliability, Satisfaction and Effectiveness of Benralizumab Home Self-Administration in Patients with Severe Eosinophilic Asthma in Real-World Practice: The Auto-Benra Study

García-Moguel¹,

Rosado²,

Gómez-Cardeñosa³

et al. 2022

JAA

View full text Add to dashboard Cite

Introduction The increase in drugs available for severe uncontrolled asthma and the lifestyle of these patients make it necessary to implement self-administration programs of these therapies at home. Benralizumab, a monoclonal antibody targeting IL5R, was authorized in Spain for poorly controlled severe eosinophilic asthma. The possibility of administration at home was approved in March 2020 in Spain. The aim of the Auto-Benra study was to evaluate the usability and satisfaction of the benralizumab prefilled syringe and autoinjector and assessing the effectivity of these devices in uncontrolled severe eosinophilic asthma (SEA) in home-self administration. Methods This is a retrospective, observational multicenter study uncontrolled SEA patients treated with benralizumab at least with 3 doses self-administered at home before April 30, 2021. Reliability and satisfaction with benralizumab at home were evaluated with subcutaneous administration assessment questionnaire (SQAAQ) and visual analogic scales (VAS). Effectiveness was evaluated in all patients with asthma control test (ACT), Mini Asthma Quality of Life Questionnaire (MiniAQLQ), annual exacerbation rate, oral corticosteroid treatment (OCS) and asthma-related hospitalizations and emergency visits. Results Fifty-four patients across 9 hospitals in Spain were included. The mean SQAAQ score was 6.89 (±0.16) points. Patients and their caregivers and doctors report excellent satisfaction by VAS, with no differences between benralizumab devices used (prefilled syringe and autoinjector). Severe exacerbation rate decreased by 65% (p = 0.0007) after benralizumab treatment. ACT score improved on average 6.27 ± 5.35 points (p < 0.0001) and the mean MiniAQLQ increased up to 1.58 ± 1.47 points (p < 0.0001). Twenty-four patients were OCS-dependent and at the end of study 14 patients get complete OCS withdrawal. Conclusion AUTO-BENRA study supports the use of benralizumab at home given the excellent results of satisfaction and usability by patients and their caregivers.

show abstract

“…For context, previous work also showed that oscillometry detected airway functional improvements in benralizumab-treated patients before or in the absence of spirometry improvements. 45 Taken together, these findings suggest that the mechanism of action of benralizumab may involve the peripheral airways, even in patients with substantial mucus plugging. Importantly, baseline VDP, and not R 5-19Hz , predicted response to treatment, suggesting that VDP may be a more sensitive measure of peripheral airway lumenization than R , where "lumenization" refers to the opening of the peripheral airways to the extent that inhaled gas can move into the corresponding lung segments.…”

Section: Discussionmentioning

confidence: 87%

Asthma Control, Airway Mucus, and 129Xe MRI Ventilation After a Single Benralizumab Dose

McIntosh

Kooner

Eddy

et al. 2022

CHEST

View full text Add to dashboard Cite

Oscillometry improves earlier than spirometry after benralizumab initiation in severe asthma

Abstract: ent. 7,8 Thus, repurposing cysteamine as a treatment for asthma may be an effective and safe treatment, even for mild asthmatics.

Cited by 15 publications

References 8 publications

Advances and recent developments in asthma in 2020

Advances and recent developments in asthma in 2020

Reliability, Satisfaction and Effectiveness of Benralizumab Home Self-Administration in Patients with Severe Eosinophilic Asthma in Real-World Practice: The Auto-Benra Study

Asthma Control, Airway Mucus, and 129Xe MRI Ventilation After a Single Benralizumab Dose

Contact Info

Product

Resources

About